title: Latin American open-label study with rabeprazole in patients with functional dyspepsia. Mexican Rabeprazole Investigators Group.
abstract: This multicenter, open-label study assessed the clinical efficacy and tolerability of the proton-pump inhibitor rabeprazole 20 mg once daily in 189 patients with functional dyspepsia and normal findings on upper endoscopy. The clinical efficacy rate was 86% after only 4 weeks of treatment, and symptoms remained under control at the end of 4 weeks without treatment. Rabeprazole was well tolerated and was associated with a low incidence (8%) of mild, transient adverse events.
authors.affiliation: Hospital Angeles del Pedregal, Mexico City, Mexico.
authors.forename: F
authors.initials: F
authors.lastname: Mundo-Gallardo
authors.forename: L
authors.initials: L
authors.lastname: De Mezerville-Cantillo
authors.forename: H
authors.initials: H
authors.lastname: Burgos-Quiroz
authors.forename: E
authors.initials: E
authors.lastname: Izquierdo
authors.forename: J
authors.initials: J
authors.lastname: Chang-Mayorga
authors.forename: L
authors.initials: L
authors.lastname: Azteguieta
authors.forename: L F
authors.initials: LF
authors.lastname: Passarrelli-Sandhoff
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D004415:Dyspepsia / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D009853:Omeprazole / Q000031:analogs & derivatives; D006180:Proton-Translocating ATPases / Q000037:antagonists & inhibitors*; D064750:Rabeprazole
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D064750:Rabeprazole; D006180:Proton-Translocating ATPases; D009853:Omeprazole